dc.contributor.author | Steyn, Dewald | |
dc.contributor.author | Du Plessis, Lissinda | |
dc.contributor.author | Kotzé, Awie | |
dc.date.accessioned | 2012-02-29T09:49:51Z | |
dc.date.available | 2012-02-29T09:49:51Z | |
dc.date.issued | 2010 | en_US |
dc.identifier.citation | Steyn, D. et al. 2010. Nasal delivery of recombinant human growth hormone: In vivo evaluation with pheroid technology and N-Trimethyl chitosan chloride. Journal of pharmacy and pharmaceutical sciences, 13(2):263-273. [https://doi.org/10.18433/J3CS3F] | en_US |
dc.identifier.issn | 1482-1826 | en_US |
dc.identifier.uri | http://hdl.handle.net/10394/6012 | |
dc.identifier.uri | https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/7425 | |
dc.identifier.uri | https://doi.org/10.18433/J3CS3F | |
dc.description.abstract | Purpose. It was the aim of this study to investigate the possible enhancement of the absorption of recombinant human growth hormone (rhGH) in the nasal cavity, in the presence of a polymeric absorption enhancer, N-trimethyl chitosan chloride (TMC) and a fatty acid-based delivery system, Pheroid™. Methods. Two types of Pheroid™ formulations, Pheroid™ vesicles and Pheroid™ microsponges were characterized and evaluated with regard to particle size and morphology. In vivo bioavailability studies in rats were performed and the nasal bioavailability of Pheroid™ vesicles and Pheroid ™microsponges were compared relative to subcutaneous administration. The results were also compared with different N-trimethyl chitosan chloride (TMC) formulations, TMC H-L and TMC H-H, well studied absorption enhancers. Results. Pheroid™ vesicles and Pheroid™ microsponges showed a size distribution of approxiamately 2-3 µm and 3-4 µm for Pheroid™ vesicles and Pheroid™ microsponges respectively. Using specific RIA, the relative bioavailability of rhGH after comparison with subcutaneous injection was determined to be 38.9, 128.5, 39.9, 136.3, and 8.3 % for Pheroid™ microsponges, Pheroid™ vesicles, TMC H-H, TMC H-L and control group (intranasal rhGH alone), respectively. All the enhancers showed significant absorption enhancement (P < 0.05) with the highest effect observed with TMC H-L. Conclusion. All the enhancers may have promising potential as safe and effective nasal absorption enhancers of rhGH | |
dc.publisher | Canadian Society for Pharmaceutical Sciences | en_US |
dc.title | Nasal delivery of recombinant human growth hormone: In vivo evaluation with pheroid technology and N-Trimethyl chitosan chloride | en_US |
dc.contributor.researchID | 11948388 - Du Plessis, Lissinda Hester | |
dc.contributor.researchID | 10200142 - Kotzé, Abraham Frederik | |
dc.contributor.researchID | 12297305 - Steyn, Johan Dewald | |